Prospects of Immunotherapy for Triple-Negative Breast Cancer

Dan Qiu; Guijuan Zhang; Xianxin Yan; Xinqin Xiao; Xinyi Ma; Shujun Lin; Jieyan Wu; Xinyuan Li; Wandi Wang; Junchen Liu; Yi Ma; Min Ma; Min Ma

doi:10.3389/fonc.2021.797092

Frontiers in Oncology (Jan 2022)

Prospects of Immunotherapy for Triple-Negative Breast Cancer

Dan Qiu,
Guijuan Zhang,
Xianxin Yan,
Xinqin Xiao,
Xinyi Ma,
Shujun Lin,
Jieyan Wu,
Xinyuan Li,
Wandi Wang,
Junchen Liu,
Yi Ma,
Min Ma,
Min Ma

Affiliations

Dan Qiu: School of Traditional Chinese Medicine of Jinan University, Jinan University, Guangzhou, China
Guijuan Zhang: School of Nursing of Jinan University, Jinan University, Guangzhou, China
Xianxin Yan: School of Traditional Chinese Medicine of Jinan University, Jinan University, Guangzhou, China
Xinqin Xiao: School of Traditional Chinese Medicine of Jinan University, Jinan University, Guangzhou, China
Xinyi Ma: School Public Health, Southern Medical University (No: 3210090112), Guangzhou, China
Shujun Lin: School of Traditional Chinese Medicine of Jinan University, Jinan University, Guangzhou, China
Jieyan Wu: School of Traditional Chinese Medicine of Jinan University, Jinan University, Guangzhou, China
Xinyuan Li: School of Medicine, Jinan University, Guangzhou, China
Wandi Wang: School of Medicine, Jinan University, Guangzhou, China
Junchen Liu: School of Medicine, Jinan University, Guangzhou, China
Yi Ma: Department of Cellular Biology, Institute of Biomedicine, National Engineering, Research Center of Genetic Medicine, Key Laboratory of Bioengineering Medicine of Guangdong Province, The National Demonstration Center for Experimental Education of Life Science and Technology, Jinan University, Guangzhou, China
Min Ma: School of Traditional Chinese Medicine of Jinan University, Jinan University, Guangzhou, China
Min Ma: The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, China

DOI: https://doi.org/10.3389/fonc.2021.797092
Journal volume & issue: Vol. 11

Abstract

Read online

In the classification and typing of breast cancer, triple-negative breast cancer (TNBC) is one type of refractory breast cancer, while chemotherapy stays in the traditional treatment methods. However, the impact of chemotherapy is short-lived and may lead to recurrence due to incomplete killing of tumor cells. The occurrence, development, and relapse of breast cancer are relevant to T cell dysfunction, multiplied expression of related immune checkpoint molecules (ICIs) such as programmed death receptor 1 (PD-1), programmed cell death 1 ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) produce immunosuppressive effect. Immunotherapy (namely, immune checkpoint inhibitors, adoptive cellular immunotherapy, CAR-T immunotherapy and some potential treatments) provides new hope in TNBC. This review focuses on the new immune strategies of TNBC patients.

Published in Frontiers in Oncology

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/

About the journal

Abstract

Keywords